Synthesis, molecular modeling and anticancer activity of new coumarin containing compounds

Morsy, Shaimaa A.; Farahat, Abdelbasset A.; Nasr, Magda N.; Tantawy, A.

doi:10.1016/j.jsps.2017.02.003

Cited by 67 publications

(39 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Geometric optimization for 3-D compounds was performed using Hyperchem release 8.0.7. hypercube Inc. The methodology used for docking was in accordance with the literature [49,50].…”

Section: Molecular Docking Methodologymentioning

confidence: 99%

Ultrasound one pot synthesis of fused quinazolinones and quinazolinediones, screening and molecular docking study as phosphodiesterase 7A inhibitors.

et al. 2019

View full text Add to dashboard Cite

P HOSPHODIESTERASE 7A enzyme is one of the most recent targets for designing potent anti-inflammatory agents with minimal side effects. Quinazolinones are unique building blocks of wide biological activities. Different quinazolinones were reported to act as Phosphodiesterase 7A inhibitors anti-inflammatory particularly against chronic inflammation and autoimmune disease. Ultrasound is a green convenient method for synthesis of different heterocyclic ring system that is advantageous in terms of yield and reaction time. Ultrasound was used for one pot synthesis of 3-substituted 6-aryldihydroisoindolo[2,1-a] quinazolin-5,11diones and 3-arylquinazolin-2,4(1H,3H)-diones. Seventeen compounds were synthesized in good yields. The synthesized compounds were inspected for in vitro inhibitory activity against phosphodiesterase7A enzyme. Molecular docking was used to study the mode of interaction of all the synthesized compounds into the enzyme phosphodiesterase 7A binding site. Five compounds showed high inhibitory activity of enzyme Phosphodiesterase 7A at micro-molar level compared to reference drug. The compounds showed good recognition at the enzyme binding site in the molecular docking. There was a good agreement between the molecular docking and the biological screening results.

show abstract

“…Geometric optimization for 3-D compounds was performed using Hyperchem release 8.0.7. hypercube Inc. The methodology used for docking was in accordance with the literature [49,50].…”

Section: Molecular Docking Methodologymentioning

confidence: 99%

Ultrasound one pot synthesis of fused quinazolinones and quinazolinediones, screening and molecular docking study as phosphodiesterase 7A inhibitors.

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Coumarin's reduction of melanoma recurrence and inhibition of renal-cell carcinoma did not withstand corroborating trials [37]. Coumarin has dose dependent cytotoxicity against the Hep2 cell line [39]. Carbon-4 substituted coumarins are antiproliferative against breast and liver carcinomas [39].…”

Section: Phenolsmentioning

confidence: 98%

“…Coumarin has dose dependent cytotoxicity against the Hep2 cell line [39]. Carbon-4 substituted coumarins are antiproliferative against breast and liver carcinomas [39]. Carbon-4 substituted coumarins inhibit aromatase, protein kinase, quinone reductase induction, sulphatase, 17β-HSD3, Cdc25, DNA intercalation, HDACs, Hsp90, microtubulin, NF-κβ, and TNF-α [40].…”

Section: Phenolsmentioning

confidence: 99%

“…Carbon-4 substituted coumarins are also down regulating selective estrogen receptor modulators (SERMs) [40]. A synthetic coumarin with a 4-position methylene thiol linker to a 6-membered heteroaromatic ring (4-Hydrazinyl-2-{[(6-methyl-2-oxo-2H-chromen-4-yl) methyl]sulfanyl}-6-phenylpyrimidine-5-carbonitrile) is cytotoxic to MCF-7 breast cancer and HepG2 hepatocarcinoma cells, IC50 5.5 mg/ml and 6.9 mg/ml, respectively [39]. Potential cytotoxicity is indicated with IC50 of 4 μg/ml or 10 μM or less [41].…”

Section: Phenolsmentioning

confidence: 99%

See 1 more Smart Citation

Nutraceuticals: Curative Integrative Cancer Treatment

Nwanodi¹

2017

Altern Integr Med

View full text Add to dashboard Cite

Statement of Purpose: Although 75% of breast cancer patients may use integrative medicine, only 11.5% earlystage breast cancer patients believe integrative medicine has anticancer activity. The gap in users of and firm believers in integrative medicine indicates a need to increase awareness of integrative medicine's applicability to curative cancer treatment. As diet, nutraceuticals, and traditional Chinese medicine are used by up to 82% of cancer patients who use integrative medicine, this paper focuses on nutraceuticals. As female cancer patients are most likely to use integrative medicine, nutraceuticals specific to breast, cervical, endometrial, and ovarian cancer are reviewed.Methods: PubMed searches in September 2016 and January 2017, and accompanying hand searches were performed for English language, free full text articles published from 2012 onwards. Search terms were combinations of the key words: Homeopathy, phytochemicals, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, cancer, prevention, treatment. Curative nutraceutical treatments were taken from these searches. Supplemental hand searches were performed as needed. Findings:Integrative nutraceutical therapies are based on biologic plausibility. Individual nutraceuticals are frequently comprised of numerous phytochemical types, and have multiple mechanisms of action. Agonistantagonist mechanisms are not exclusive to phytoestrogens, complicating which derivative or whole nutraceutical to use. Research on breast and cervical cancer inhibitors has seemingly outpaced that for endometrial and ovarian cancer. Breast cancer inhibitors include terpenes, isoflavones, organosulphurs, organoselenium compounds, and withanolides. Conclusion and Significance:Potential nutraceutical candidates for curative cancer treatment abound. Discerning which constituents, which extraction method, and which delivery method to use for an efficacious treatment is an essential, lengthy process. If nutraceuticals such as limonene and Kahalalide F move forward to Phase III trials a nutraceutical cancer treatment pipeline may be established. Withaferin-A and derivatives for breast and ovarian cancer appear to be the leading gynecologic cancer nutraceutical drug candidates.

show abstract

“…Vincristine (Figure 4) is used for the treatment of acute lymphoblastic leukaemia and both Hodgkin's and-non-Hodgkin's lymphoma. 12 Scheme 8 Shows the synthetic steps of amino chloropyrano oxazine compounds and the graphical results showing the effects of these compounds on different types of cancer cells. The development in heterocyclic compounds its utility and applications toward cancer screening studies showed a lot of works in this area of drug discovery as an examples coumarin and oxazine compounds.…”

Section: Heterocyclic Compounds In Anti-cancer Drug Design Strategymentioning

confidence: 99%

Untitled

2019

OAJS

View full text Add to dashboard Cite

Polymers and heterocyclic compounds play an important role in pharmacy according to their functions as excipients and inert carriers of other pharmacological active compounds. This review article discuss the recent developments in using this compounds in pharmaceuticals applications as active compounds in both as co drug or drug carriers as well as in delivery systems concerning drug therapy. These polymers and heterocyclic compounds according to their chemical character play important rules in many biological system and that is why we are here discussing there importance in many biological events such as anti microbial, antihyperkalemia and anti cancer agents.

show abstract

Synthesis, molecular modeling and anticancer activity of new coumarin containing compounds

Cited by 67 publications

References 35 publications

Ultrasound one pot synthesis of fused quinazolinones and quinazolinediones, screening and molecular docking study as phosphodiesterase 7A inhibitors.

Ultrasound one pot synthesis of fused quinazolinones and quinazolinediones, screening and molecular docking study as phosphodiesterase 7A inhibitors.

Nutraceuticals: Curative Integrative Cancer Treatment

Untitled

Contact Info

Product

Resources

About